GSK Links With Adaptimmune In Oncology Intracellular TCR R&D Pact
This article was originally published in The Pink Sheet Daily
GlaxoSmithKline has entered a long-term cell-based immunotherapy collaboration with T cell receptor specialist Adaptimmune, signaling the Big Pharma player is still investing in cutting-edge oncology R&D.
You may also be interested in...
AstraZeneca has vowed to slash its carbon emissions to zero by 2025 and ensure its entire value chain is carbon negative by 2030. It will spend up to $1bn to do so.
The Novo Nordisk Foundation is sponsoring a panel at Davos this week on finding solutions to the global crisis on antimicrobial resistance – and hopes world leaders will listen.
A Phase III clinical trial comparing AbbVie's Skyrizi with Novartis's IL-17 agonist Cosentyx showed the former's superiority in adults with moderate-to-severe plaque psoriasis.